Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2021-08-11 Report Publication Anno…
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Reports Second Quarter and First Half 2021 Financial Results
Report Publication Announcement Classification · 1% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. It references 'Kamada Reports Second Quarter and First Half 2021 Financial Results' and mentions an attached PDF file. Since the document itself is short and serves to announce the publication of a detailed financial report (Second Quarter and First Half results), it fits the definition of a Report Publication Announcement (RPA). It is not the full Interim Report (IR) itself, but the announcement of its release.
2021-08-11 English
Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021
Earnings Release Classification · 1% confidence The document is a Form 6-K filed with the SEC by a Foreign Private Issuer (Kamada Ltd.). The core content attached as Exhibit 99.1 is a press release announcing the upcoming release of 'Second Quarter and First Half 2021 Financial Results' and the hosting of a conference call. This announcement of upcoming financial results, which precedes the actual detailed report (like an IR or 10-K), fits the definition of an Earnings Release (ER) announcement, or more broadly, a document primarily focused on announcing financial results. However, the primary filing type is Form 6-K, which is a general report for foreign private issuers. Since the content is an announcement of quarterly results and a conference call, it strongly aligns with the purpose of an Earnings Release (ER). The document itself is not the full financial report (IR) or the transcript (CT), but the announcement of the results release date. Given the options, ER is the most specific fit for the *content* being announced, even though the *form* is 6-K. Since 6-K is not an option, we classify based on the subject matter being disseminated. If the document were the actual results, it would be IR. Since it is the announcement of the results release date, it functions as an Earnings Release announcement. The document length (6391 chars) is substantial enough that it's more than just a brief notice, but the primary purpose is clearly tied to the upcoming earnings disclosure. H1 2021
2021-08-05 English
Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021
Report Publication Announcement Classification · 1% confidence The document is a very short announcement (1954 characters) filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The core content states: "Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021". It explicitly mentions that a report is attached ("Attached hereto is a report on..."). This structure—announcing the future release of results and attaching a brief notice—fits the definition of a Report Publication Announcement (RPA), as it is not the full financial report itself (like an IR or 10-K), but rather the announcement of its upcoming release/publication.
2021-08-05 English
FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children”
Regulatory Filings Classification · 1% confidence The document is explicitly identified as a "FORM 6-K" filed with the SEC by Kamada Ltd. for the month of June 2021. Form 6-K is used by Foreign Private Issuers to report material information to the SEC that they are required to disclose to their home country's stock exchange or make public in their home country. The content attached as Exhibit 99.1 is a press release announcing an FDA label update for the product KEDRAB®. Since this is a filing that transmits material information (a press release) to the SEC on a periodic basis (monthly filing structure), and it does not fit the specific definitions for 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report), it falls best under the general category for regulatory filings that are not otherwise specified. While it contains an announcement, the primary document structure is the SEC Form 6-K submission itself, which is a mandatory regulatory filing. Given the available codes, 'RNS' (Regulatory Filings) is the most appropriate fallback for a Form 6-K that is not a core financial statement report, especially since the content is a press release announcement. However, upon reviewing the definitions, Form 6-K is a standard SEC filing for foreign private issuers. If the content were purely an earnings announcement, ER might apply, but this is a specific product/FDA update. Since there is no specific code for Form 6-K, and it is a regulatory submission, RNS is the best fit as the general regulatory filing category.
2021-06-02 English
FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children”
Report Publication Announcement Classification · 1% confidence The document is very short (1954 characters) and explicitly states that it is an 'Immediate Report' under Israeli regulations. The key phrase is: 'Attached hereto is a report on*�Kedrion and Kamada Announce FDA Approval of KEDRAB� Label Update, Confirming Safety and Effectiveness in Children�*'. This structure—a brief announcement stating that a substantive report is attached or linked—fits the definition of a Report Publication Announcement (RPA) according to Rule 2 ('MENU VS MEAL' rule). It is not the full report itself, but the notice of its publication.
2021-06-02 English
Kamada Reports First Quarter 2021 Financial Results
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Kamada Ltd. It contains the company's quarterly financial results for the period ending March 31, 2021, including consolidated financial statements and a detailed management discussion of financial highlights. While it is filed as a 6-K, the content constitutes a comprehensive quarterly financial report with substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.